- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Rolf Benirschke: Access to Biologics for IBD
Rolf Benirschke, chief executive officer of Legacy Health Strategies, discusses the challenges patients face in getting access to biologics to treat inflammatory bowel disease.
Transcript:
Patients face a lot of challenges when it comes to getting on therapy, particularly some of the biologics. What we're finding is that, physicians, particularly the sophisticated physicians, a lot of the academic institutions, are able to subjectively figure out which patients will respond to which biologic, but if they go to prescribe that biologic, oftentimes, the insurers will not allow the patient to get on it until they fail another therapy.
So it’s this fail-first therapy before they get access to it. That's frustrating for the patient, and frustrating for the physician. If the physician is pretty good at determining that this patient likely will not do well, in his mind, why does that patient have to fail first?
Also, it’s tough for the patient. They go through a regimen that doesn't work, their disease progresses, gets more entrenched, and then it’s a more difficult disease to face. So that’s one of the big challenges currently.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
